StimuSIL to Present First Clinical Evidence for Multiple Hair Rejuvenation Technologies at ASLMS 2026
Delaware, US; Feb 12st, 2026
Company’s StimuField™ PEMF wearable cap and SAGA™ intradermal laser technologies selected for presentation at the world’s most influential conference for energy-based devices in medical aesthetics
StimuSIL, Inc., a biomedical device company developing innovative non-pharmaceutical solutions for hair wellness and rejuvenation, today announced that three research abstracts have been accepted for presentation at the 45th Annual Conference of the American Society for Laser Medicine and Surgery (ASLMS), to be held May 7–9, 2026, in Savannah, Georgia.
The accepted research covers both of StimuSIL’s core technologies: the StimuField PEMF cap, a home-use non-laser wellness device for hair thinning, and SAGA-001, a novel clinic-based intradermal laser for the treatment of androgenetic alopecia.
ASLMS is the world’s largest professional organization dedicated to laser and energy-based technologies in medicine, with its official journal, Lasers in Surgery and Medicine, ranked in the top quartile of both Dermatology and Surgery journals worldwide. All accepted abstracts will be published in a peer-reviewed supplement of Lasers in Surgery and Medicine.
Accepted Abstracts
“Efficacy and Safety of a Novel PEMF Wearable Cap for the Management of Hair Thinning: A Prospective Case Series” (Oral Presentation). This 24-week prospective study found that subjects using the StimuField PEMF cap demonstrated a mean increase of 23 terminal hairs per square centimeter, with individual improvements reaching up to 47%. All subjects achieved hair loss stabilization or reversal, and 80% reported fuller, thicker hair. No serious adverse events were reported.
“Safety and Efficacy of an Intradermal Laser Delivered via Transparent Microneedles for Androgenetic Alopecia: A Randomized Controlled Pilot Study” (Oral Presentation). This 82-patient randomized controlled pilot study conducted across two university hospital centers in Turkey demonstrated that the SAGA-001 intradermal laser safely stabilized terminal hair density in patients with androgenetic alopecia. The device achieved zero serious adverse events across 939 total treatments, with 89% of patients reporting moderate-to-high improvement in hair appearance.
“Novel Intradermal Laser Device via Polymer Microneedles: Mechanism of Action and Technical Validation for Follicular Stimulation” (ePoster). This basic science abstract details the engineering and validation of the SAGA-001 device, a first-in-kind intradermal laser that uses transparent polymer microneedles to deliver light directly to the follicular dermis, bypassing the melanin layer with approximately 90% optical transmission efficiency.
“Having our clinical data on the StimuField PEMF cap selected for an oral presentation at ASLMS is a significant milestone,” said Dr. Scott Gerrish, Chief Medical Officer of StimuSIL and presenting author for both clinical abstracts. “The results show that daily PEMF therapy can meaningfully improve hair density in a convenient, at-home format. At the same time, our SAGA intradermal laser data from 82 subjects demonstrates that we can safely deliver light energy past the skin’s barriers to directly target hair follicles. These are two complementary approaches that together represent a new standard for non-pharmaceutical hair rejuvenation.”
“Being recognized by the leading professional society in laser and energy-based medicine validates years of research and development by our team,” said Ana Villalba Villar, CEO of StimuSIL. “We are building a multi-modal platform for hair health, with StimuField serving people at home and SAGA equipping clinicians with a powerful in-office treatment. Having three abstracts accepted at ASLMS gives us a strong foundation to expand and accelerate our partnerships, ultimately bringing these solutions to more people worldwide.”
The oral presentations will be delivered during the ASLMS conference in Savannah by Dr. Scott Gerrish and Dr. Mehmet Kosoglu, StimuSIL’s Chief Scientific Officer. The SAGA-001 clinical study was conducted in collaboration with Istanbul University Cerrahpaşa Medical Faculty and Ankara Bilkent City Hospital.
About StimuSIL
StimuSIL is a biomedical device company dedicated to developing safer, more effective electromagnetic and light-based therapies for dermatology and aesthetics, backed by clinical research. The company’s product portfolio includes StimuField, a wireless home-use PEMF cap designed to support hair wellness, and SAGA-001, a clinic-based intradermal laser device currently in regulatory development. StimuSIL is headquartered in Wilmington, Delaware. For more information, visit stimusil.com and stimufield.com.
About ASLMS
The American Society for Laser Medicine and Surgery, founded in 1980, is the world’s largest professional organization dedicated to promoting research, education, and high standards of clinical care in the field of medical laser and energy-based applications. The ASLMS Annual Conference is the largest conference in the United States dedicated to laser and energy-based technologies in medicine.
Media Contact: StimuSIL, Inc. stimufield@stimusil.com
Important Notice: The StimuField PEMF cap is a wellness device designed for general health and well-being purposes. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. SAGA-001 is an investigational device not yet cleared or approved by the FDA.